Press releases

Q4 adjusted results in line with expectations; Company well positioned for 2009 and beyond Company records $2.7 billion goodwill impairment charge NATICK, Mass., Jan. 28 /PRNewswire-FirstCall/ --...

Boston Scientific Corporation announced today that it has received approval from the...

Agreement stops all litigation in interventional cardiology and endovascular repair NATICK, Mass., Jan. 27 /PRNewswire-FirstCall/ -- Boston Scientific Corporation and Medtronic, Inc. today...

Boston Scientific Corporation today announced it has been awarded a contract by the U.S. Department of Veterans Affairs (VA) for a full line of the...

Boston Scientific Corporation today announced a decision by the Court of Appeals for the Federal Circuit. The case involves a Boston Scientific...

Boston Scientific Corporation will webcast its conference call discussing financial results for the fourth quarter and the year ended December 31,...

Boston Scientific Corporation is scheduled to participate in the upcoming JP Morgan Health Care Conference in San Francisco. Jim Tobin, Chief...

Acquisition demonstrates Company's commitment to innovation in drug-eluting stent technology NATICK, Mass., Jan. 6 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced that it...

Boston Scientific Corporation today announced enrollment of the first patient...

Boston Scientific Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved the Express® SD Renal Monorail®...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Piper Jaffray Health Care Conference, which is being held December 2 -...

Boston Scientific Corporation (NYSE: BSX) today announced that it has received approval from the U.S. Food and Drug Administration to market its...

Boston Scientific Corporation (NYSE: BSX) today welcomed passage of legislation to help active members of the U.S. armed forces and service...

Boston Scientific Corporation (NYSE: BSX) today welcomed an announcement by the U.K.'s National Institute for Health and Clinical Excellence (NICE)...

Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved its Carotid WALLSTENT®...

Boston Scientific Corporation (NYSE: BSX) today announced financial results for the third quarter ended September 30, 2008, as well as guidance for...

Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of the HORIZONS AMI trial. The HORIZONS AMI...

Boston Scientific Corporation (NYSE: BSX) today announced positive one-year results from the Intercontinental and European launch...

Boston Scientific Corporation (NYSE: BSX) today announced 12-month left main and three-vessel disease subset data from its landmark...

Boston Scientific Corporation (NYSE: BSX) today provided the following comments reinforcing the strength of its balance sheet: The volatility of...

Boston Scientific Corporation (NYSE: BSX) today announced estimated U.S. market shares for September for its two drug-eluting stents (DES), based...

GE Healthcare (NYSE: GE) and intravascular ultrasound (IVUS) market leader Boston Scientific Corporation (NYSE: BSX) today...

Thursday and Friday of last week saw continued heavy trading in Boston Scientific's (NYSE: BSX) stock. As anticipated in the Company's October 9th...

Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of nearly 7,500 patients from its TAXUS ARRIVE 1...

Boston Scientific Corporation (NYSE: BSX) today announced comprehensive data from the TAXUS ATLAS clinical program, a series of...